1. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression
- Author
-
Nandi, Ipshita, Smith, Harvey W., Sanguin-Gendreau, Virginie, Ji, Linjia, Pacis, Alain, Papavasiliou, Vasilios, Zuo, Dongmei, Nam, Stella, Attalla, Sherif S., Kim, Sung Hoon, Lusson, Sierra, Kuasne, Hellen, Fortier, Anne-Marie, Savage, Paul, Ramirez, Constanza Martinez, Park, Morag, Katzenellenbogen, John A., Katzenellenbogen, Benita S., and Muller, William J.
- Subjects
Gene expression -- Analysis ,Breast cancer -- Diagnosis -- Development and progression ,Health care industry - Abstract
Activation of the tyrosine kinase c-Src promotes breast cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we have shown that deletion of c-Src in a genetically engineered model mimicking the luminal B molecular subtype of breast cancer abrogated the activity of forkhead box M1 (FOXM1), a master transcriptional regulator of the cell cycle. We determined that c-Src phosphorylated FOXM1 on 2 tyrosine residues to stimulate its nuclear localization and target gene expression. These included key regulators of [G.sub.2]/M cell-cycle progression as well as c-Src itself, forming a positive feedback loop that drove proliferation in genetically engineered and patient-derived models of luminal B-like breast cancer. Using genetic approaches and small molecules that destabilize the FOXM1 protein, we found that targeting this mechanism induced [G.sub.2]/M cell-cycle arrest and apoptosis, blocked tumor progression, and impaired metastasis. We identified a positive correlation between FOXM1 and c-Src expression in human breast cancer and show that the expression of FOXM1 target genes predicts poor outcomes and associates with the luminal B subtype, which responds poorly to currently approved therapies. These findings revealed a regulatory network centered on c-Src and FOXM1 that is a targetable vulnerability in aggressive luminal breast cancers., Introduction Breast cancer comprises a range of histopathological and molecular subtypes differing in metastatic capacity, response to therapies, and clinical outcomes (1). Transcriptomic profiling has identified at least 5 breast [...]
- Published
- 2023
- Full Text
- View/download PDF